Empagliflozin

Pharmacokinetic Profile: Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.

Renal Considerations: Renal: Mechanism nuances by indication! • Glycaemic lowering effect diminishes when eGFR <45 mL/min. • Heart Failure & CKD cardiorenal protection persists down to eGFR ≥20 mL/min/1.73m2 (10 mg OD). Do not initiate if eGFR <20 mL/min or on dialysis. Note: An initial benign haemodynamic dip in eGFR of 3–5 mL/min within the first 2–4 weeks is expected due to reduced intraglomerular hyperfiltration and stabilises long-term. Hepatic: No dose adjustment in mild-to-moderate impairment; avoid in severe hepatic failure.

Hepatic Considerations: Renal: Mechanism nuances by indication! • Glycaemic lowering effect diminishes when eGFR <45 mL/min. • Heart Failure & CKD cardiorenal protection persists down to eGFR ≥20 mL/min/1.73m2 (10 mg OD). Do not initiate if eGFR <20 mL/min or on dialysis. Note: An initial benign haemodynamic dip in eGFR of 3–5 mL/min within the first 2–4 weeks is expected due to reduced intraglomerular hyperfiltration and stabilises long-term. Hepatic: No dose adjustment in mild-to-moderate impairment; avoid in severe hepatic failure.

• Genital mycotic (fungal) infections (vulvovaginal candidiasis in women, balanitis/balanoposthitis in uncircumcised men—5 to 10%), urinary tract infections, osmotic polyuria/increased urination, mild postural dizziness, modest weight loss (2–3 kg) and systolic BP reduction (3–5 mmHg).
• Euglycaemic Diabetic Ketoacidosis (euDKA—ketoacidosis occurring even when blood glucose is relatively normal or mildly elevated, <200–250 mg/dL!), Fournier's gangrene (rare necrotising fasciitis of the perineum—medical emergency), acute kidney injury from volume depletion, urosepsis.

• Loop diuretics (furosemide, torsemide) increase risk of dehydration and orthostatic hypotension (diuretic dose often needs reduction when starting empagliflozin)
• Enhances hypoglycaemia if added to insulin or sulfonylureas without adjusting their dose (never abruptly stop insulin completely, as insulin deficiency triggers euDKA)
• Decreases serum lithium levels by increasing renal lithium excretion

Pregnancy, Lactation, Paediatric & Geriatric Use: Evaluate maternal-foetal benefit-risk ratio and age-appropriate organ function before prescribing.

Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

• Patient Counselling Checklist: Mandatory Perineal Hygiene Counselling: Because empagliflozin removes excess sugar through the urine, sugar on the skin encourages fungal growth—instruct every male and female patient to wash the genital area with plain clean water after every urination and keep the area dry. Reassure non-diabetic heart failure or CKD patients that empagliflozin is prescribed to protect their heart and kidneys and will not drop normal blood sugar. Enforce the Sick Day / Pre-Surgery Hold Rule (pause during fasting, vomiting, or 3 days before surgery).
• Meal & Clock Timing Instruction: With or without food (if FDC with metformin, take WITH breakfast). (Once daily in the morning (morning administration avoids osmotic nocturia at night).)
• Missed Dose Protocol: Take as soon as remembered if before mid-afternoon; if evening, skip to avoid night-time urination.
• Geriatric Dispensing Pearl: Check volume status and blood pressure in elderly patients taking concurrent loop or thiazide diuretics to prevent dehydration and orthostatic falls. Warn elderly men with BPH or women with recurrent UTIs to report burning urination or genital itching early.

Storage & Dispensing Governance: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Oral Film-Coated Tablets: 10 mg, 25 mg